相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation
Xiaohui Yan et al.
BIOCHEMICAL PHARMACOLOGY (2018)
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
A. Lisberg et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Inhibition of mTORC2 enhances UVB-induced apoptosis in keratinocytes heck fo through a mechanism dependent on the FOXO3a transcriptional target NOXA but independent of TRAIL
Robert P. Feehan et al.
CELLULAR SIGNALLING (2018)
Critical role of FOXO3a in carcinogenesis
Ying Liu et al.
MOLECULAR CANCER (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Ferdinandos Skoulidis et al.
CLINICAL CANCER RESEARCH (2017)
Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer
Jeroen E. Guikema et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Study on the Pulmonary Delivery System of Apigenin-Loaded Albumin Nanocarriers with Antioxidant Activity
Zsofia Edit Papay et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells
Guangming Zhao et al.
ONCOLOGY REPORTS (2017)
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
Dae Ho Lee
PHARMACOLOGY & THERAPEUTICS (2017)
Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
Xiaohui Yan et al.
CELL AND BIOSCIENCE (2017)
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer
Hiroshi Mizuuchi et al.
CANCER SCIENCE (2016)
EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
E-E Ke et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner
Minghui Chen et al.
SCIENTIFIC REPORTS (2016)
Apigenin ameliorates hypertension-induced cardiac hypertrophy and down-regulates cardiac hypoxia inducible factor-lα in rats
Zeng-Yan Zhu et al.
FOOD & FUNCTION (2016)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein et al.
CANCER RESEARCH (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines
A. A. Mahbub et al.
CELL DEATH DISCOVERY (2015)
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
S. E. D. C. Jorge et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion
Shu-min Ding et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2014)
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
J. L. Kuiper et al.
LUNG CANCER (2014)
Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa
Xiaohui Wang et al.
ONCOLOGY REPORTS (2014)
Rebiopsy of Non-Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Akito Hata et al.
CANCER (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells
Yuan-Chuen Wang et al.
FOOD AND CHEMICAL TOXICOLOGY (2013)
Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737
Darcy J. P. Bates et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Huanjie Shao et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids
Berrin Ozcelik et al.
PHARMACEUTICAL BIOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
14-3-3ε antagonizes FoxO to control growth, apoptosis and longevity in Drosophila
Mette Damgaard Nielsen et al.
AGING CELL (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Chemical Genetic Analysis of FOXO Nuclear-Cytoplasmic Shuttling by Using Image-Based Cell Screening
Fabian Zanella et al.
CHEMBIOCHEM (2008)
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Jer-Yen Yang et al.
NATURE CELL BIOLOGY (2008)
ErbB receptors: from oncogenes to targeted cancer therapies
Hongtao Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
An integrated mass spectrometric and computational framework for the analysis of protein interaction networks
Oliver Rinner et al.
NATURE BIOTECHNOLOGY (2007)
FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells
P. Obexer et al.
CELL DEATH AND DIFFERENTIATION (2007)
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
Takayuki Kosaka et al.
CLINICAL CANCER RESEARCH (2006)
FOXO transcription factors at the interface between longevity and tumor suppression
EL Greer et al.
ONCOGENE (2005)
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin
SZ Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration
A Gradolatto et al.
DRUG METABOLISM AND DISPOSITION (2005)
分享论文
